| Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes W Schroth, L Antoniadou, P Fritz, M Schwab, T Muerdter, UM Zanger, ... Journal of Clinical Oncology 25 (33), 5187-5193, 2007 | 590 | 2007 |
| Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy W Solass, R Kerb, T Mürdter, U Giger-Pabst, D Strumberg, C Tempfer, ... Annals of surgical oncology 21, 553-559, 2014 | 395 | 2014 |
| Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 J Kirchheiner, C Klein, I Meineke, J Sasse, UM Zanger, TE Mürdter, ... Pharmacogenetics and Genomics 13 (10), 619-626, 2003 | 314 | 2003 |
| Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine T Richter, TE Mürdter, G Heinkele, J Pleiss, S Tatzel, M Schwab, ... Journal of Pharmacology and Experimental Therapeutics 308 (1), 189-197, 2004 | 305 | 2004 |
| Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma TE Mürdter, W Schroth, L Bacchus‐Gerybadze, S Winter, G Heinkele, ... Clinical Pharmacology & Therapeutics 89 (5), 708-717, 2011 | 299 | 2011 |
| Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer P Saladores, T Mürdter, D Eccles, B Chowbay, NK Zgheib, S Winter, ... The pharmacogenomics journal 15 (1), 84-94, 2015 | 209 | 2015 |
| Pharmacogenomics of tamoxifen therapy H Brauch, TE Murdter, M Eichelbaum, M Schwab Clinical chemistry 55 (10), 1770-1782, 2009 | 206 | 2009 |
| P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans S Drescher, H Glaeser, T Mürdter, M Hitzl, M Eichelbaum, MF Fromm Clinical Pharmacology & Therapeutics 73 (3), 223-231, 2003 | 200 | 2003 |
| Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy MH Olofsson, T Ueno, Y Pan, R Xu, F Cai, H Van Der Kuip, TE Muerdter, ... Clinical Cancer Research 13 (11), 3198-3206, 2007 | 178 | 2007 |
| The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liver JK Coller, N Krebsfaenger, K Klein, K Endrizzi, R Wolbold, T Lang, ... British journal of clinical pharmacology 54 (2), 157-167, 2002 | 172 | 2002 |
| Role of P-Glycoprotein Inhibition for Drug Interactions: Evidence from In Vitro and Pharmacoepidemiological Studies S Eberl, B Renner, A Neubert, M Reisig, I Bachmakov, J König, F Dörje, ... Clinical pharmacokinetics 46, 1039-1049, 2007 | 148 | 2007 |
| Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment H van der Kuip, TE Mürdter, M Sonnenberg, M McClellan, S Gutzeit, ... BMC cancer 6, 1-11, 2006 | 140 | 2006 |
| Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters H Brauch, W Schroth, MP Goetz, TE Mürdter, S Winter, JN Ingle, ... Journal of Clinical Oncology 31 (2), 176, 2013 | 139 | 2013 |
| Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib SS Brenner, C Herrlinger, K Dilger, TE Mürdter, U Hofmann, C Marx, ... Clinical pharmacokinetics 42, 283-292, 2003 | 117 | 2003 |
| Expression and function of β-glucuronidase in pancreatic cancer: potential role in drug targeting B Sperker, U Werner, TE Mürdter, C Tekkaya, P Fritz, R Wacke, U Adam, ... Naunyn-Schmiedeberg's Archives of Pharmacology 362, 110-115, 2000 | 110 | 2000 |
| Enhanced uptake of doxorubicin into bronchial carcinoma: β-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site TE Mürdter, B Sperker, KT Kivistö, M McClellan, P Fritz, G Friedel, ... Cancer research 57 (12), 2440-2445, 1997 | 109 | 1997 |
| Genetic polymorphisms of glutathione S‐transferase A1, the major glutathione S‐transferase in human liver: consequences for enzyme expression and busulfan conjugation M Bredschneider, K Klein, TE Mürdter, C Marx, M Eichelbaum, AK Nüssler, ... Clinical Pharmacology & Therapeutics 71 (6), 479-487, 2002 | 105 | 2002 |
| The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2′-O-methyl-RNA directed against telomerase in lung cancer cells S Taetz, N Nafee, J Beisner, K Piotrowska, C Baldes, TE Mürdter, ... European journal of pharmaceutics and biopharmaceutics 72 (2), 358-369, 2009 | 85 | 2009 |
| Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts S Haubeiss, JO Schmid, TE Mürdter, M Sonnenberg, G Friedel, ... Molecular cancer 9, 1-8, 2010 | 81 | 2010 |
| Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. I Siegle, P Fritz, M McClellan, S Gutzeit, TE Mürdter Anticancer research 21 (4A), 2687-2691, 2001 | 81 | 2001 |
